Michelle L. Apperson, M.D., Ph.D.

Clinical Professor

Director, UC Davis Multiple Sclerosis Program

To see if Michelle L. Apperson is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Reviews

Specialties

Multiple Sclerosis

Neurology - Neuroimmunology

Department

Neurology

Locations and Contact

UC Davis Midtown Ambulatory Care Center

Midtown Neurology Clinic
3160 Folsom Blvd
Sacramento, CA 95816

Get Directions

Phone: 916-734-3588

Additional Numbers

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Apperson's clinical interests include: General Neurology, Multiple Sclerosis, and Neuromyelitis Optica.

Research/Academic Interests

Dr. Apperson's research interests include clinical trials of novel multiple sclerosis treatments and identification of multiple sclerosis biomarkers.

Dr. Apperson is conducting genetic, genomic and other biochemical blood profiling to further elucidate the relationship between genetics and environmental factors in the autoimmune etiology of multiple sclerosis.

Division

Neurology

Undergraduate School

B.A., UC San Diego, San Diego CA 1988

Medical School

M.D., University of Hawaii, John A. Burns School of Medicine, Manoa HI 2001

Other School

Ph.D., Philosophy, California Institute of Technology, Pasadena CA 1996

Internship

Internal Medicine, University of Hawaii at Manoa, Honolulu HI 2001-2002

Residency

Neurology, UC Davis Medical Center, Sacramento CA 2002-2005

Fellowship

Neurology/Multiple Sclerosis, UC Davis Medical Center, Sacramento CA 2005-2008

UC Davis Neurology Senior Resident Appreciation Award, 2010, 2015

Sylvia Lawry Physician Fellow of the National Multiple Sclerosis Society, 2006-2008,

Chief Residency at UC Davis Neurology Residency Program, 2004

Yuan O, Lin C, Wagner J, Archard JA, Deng P, Halmai J, Bauer G, Fink KD, Fury B, Perotti NH, Walker JE, Pollock K, Apperson M, Butters J, Belafsky P, Farwell DG, Kuhn M, Nolta J, Anderson JD. Exosomes Derived from Human Primed Mesenchymal Stem Cells Induce Mitosis and Potentiate Growth Factor Secretion. Stem Cells Dev. 2019 Mar 15;28(6):398-409. doi:10.1089/scd.2018.0200. Epub 2019 Feb 26. PMID:30638129.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med. 2018 Aug 30;379(9):846-855. doi:10.1056/NEJMoa1803583. PMID:30157388.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263-1273. doi:10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170. PMID:29576505.

Derlet A, Agius M, Apperson ML. Symptomatic Thrombocytopenia After One Dose of Alemtuzumab With Successful Rechallenge. Neurology. 2017 Apr 27;88(16 Supplement) P5.400.

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015 Mar 17;84(11):1145-52. doi:10.1212/WNL.0000000000001360. Epub 2015 Feb 13. PMID:25681448.

Parish MB, Apperson M, Yellowlees PM. Engaging U.S. veterans with PTSD in online therapy. Psychiatr Serv. 2014 May 1;65(5):697. doi:10.1176/appi.ps.650501. PMID:24788736.

Apperson ML, Tian Y, Stamova B, Ander BP, Jickling GC, Agius MA, Sharp FR. Genome wide differences of gene expression associated with HLA-DRB1 genotype in multiple sclerosis: a pilot study. J Neuroimmunol. 2013 Apr 15;257(1-2):90-6. doi:10.1016/j.jneuroim.2013.02.004. Epub 2013 Mar 9. PMID:23477965.

Dias RA, Hardin KA, Rose H, Agius MA, Apperson ML, Brass SD. Sleepiness, fatigue, and risk of obstructive sleep apnea using the STOP-BANG questionnaire in multiple sclerosis: a pilot study. Sleep Breath. 2012 Dec;16(4):1255-65. doi:10.1007/s11325-011-0642-6. Epub 2012 Jan 21. PMID:22270686.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi:10.1056/NEJMoa1206328. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673. PMID:22992072.

Magley J, Towner D, Taché V, Apperson ML. Pregnancy outcome in anti-N-methyl-D-aspartate receptor encephalitis. Obstet Gynecol. 2012 Aug;120(2 Pt 2):480-483. doi:10.1097/AOG.0b013e31825935d4. PMID:22825272.